Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Liječenj kroničnog B hepatitisa (CROSBI ID 163363)

Prilog u časopisu | stručni rad

Morović, Miro ; Trošelj-Vukić, Biserka ; Klarin, I ; Hrstić, I ; Ostojić, Ranko Liječenj kroničnog B hepatitisa // Acta medica Croatica, 63 (2009), 5; 391-395

Podaci o odgovornosti

Morović, Miro ; Trošelj-Vukić, Biserka ; Klarin, I ; Hrstić, I ; Ostojić, Ranko

hrvatski

Liječenj kroničnog B hepatitisa

Chronic hepatitis B is associated with the development of cirrhosis in more than one third of patients and in a large proportion of patients with hepatocellular carcinoma. Current standard treatment includes pegylated interferon alfa-2a and five oral nucleoside/nucleotide analogues: entecavir, tenofovir, adefovir, telbivudine and lamivudine (listed according to antiviral efficacy). The advantage of interferon treatment is the possibility of long-term remission in one third of carefully selected HbeAg+ patients without development of resistance. However, interferon treatment is not efficient in the majority of patients. The advantage of treatment with nucleoside and nucleotide analogues is the possibility to suppress HBV DNA to undetectable levels in 70%-90% of patients. However, analogue treatment is a long-term treatment (possibly life-long) and is associated with the development of resistance.

*

nije evidentirano

engleski

Chronic hepatitis B therapy

nije evidentirano

*

nije evidentirano

Podaci o izdanju

63 (5)

2009.

391-395

objavljeno

1330-0164

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost